Evidence map›Paper›PMID 29597343›Full record

ArticleACS chemical neuroscience2018

Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats.

Callum Hicks, Peng Huang, Linnet Ramos, Sunil U Nayak, Yohanka Caro, Allen B Reitz, Garry R Smith, David Y-W Lee, Scott M Rawls, Lee-Yuan Liu-Chen

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Natural Product-Inspired Dopamine Receptor Ligands.Journal of medicinal chemistry · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. A critical review: traditional uses, phytochemistry, pharmacology and toxicology ofPhytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2020
    Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Callum HicksDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.ORCID 0000-0002-6144-8883
Peng HuangDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Linnet RamosDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Sunil U NayakDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Yohanka CaroDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Allen B ReitzFox Chase Chemical Diversity Center, Doylestown , Pennsylvania 18902 , United States.
Garry R SmithFox Chase Chemical Diversity Center, Doylestown , Pennsylvania 18902 , United States.
David Y-W LeeBio-Organic and Natural Products Laboratory , McLean Hospital, Harvard Medical School , Belmont , Massachusetts 02478 , United States.
Scott M RawlsDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Lee-Yuan Liu-ChenDepartment of Pharmacology , Temple University School of Medicine , Philadelphia , Pennsylvania 19140 , United States.
Temple University · USFox Chase Chemical Diversity Center · USHarvard University · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Munir Gunes Kutlu · 2000 to 2026
$34.6M
TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Mechanism of Action of L THP as an Alternative Therapy for Cocaine AddictionR01AT006899 · NCCIH · MCLEAN HOSPITAL · PI LEE, DAVID YUE-WEI, LIU-CHEN, LEE-YUAN · 2012 to 2016
$2.1M
Psychoactive bath salts and the glutamate systemR01DA039139 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI RAWLS, SCOTT M. · 2015 to 2019
$1.8M
Kappa opioid receptor in claustrumR21DA045274 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI LIU-CHEN, LEE-YUAN · 2018 to 2019
$436k
NCCIH NIH HHS R01 AT006899NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA039139NIDA NIH HHS R21 DA045274NIDA NIH HHS T32 DA007237
6 · The paper itself

Abstract

Psychostimulant reinforcement is mediated by stimulation of both dopamine (DA) D1-like and D2-like receptors, suggesting that pharmacotherapy agents with a dual DA receptor mechanism may be useful for managing psychostimulant abuse. (-)-Stepholidine (L-SPD) is a Chinese herbal extract that functions as a D1-like receptor agonist and D2-like receptor antagonist. L-SPD has been shown to attenuate the reinforcing effects of heroin; however, its effects on the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) have not been examined. The current study determined the effects of L-SPD on reinstatement of MDPV-seeking behavior in the drug intravenous self-administration (IVSA) and conditioned place preference (CPP) paradigms. To determine whether the effects of L-SPD were specific to psychostimulant reinforcement, we also examined its effects on sucrose-seeking behavior. Using a locomotor activity assay, we tested the locomotor effects of L-SPD, as well as its effects on MDPV-induced hyperactivity. The results of a battery of in vitro binding and functional assays confirmed that L-SPD functioned as a D1-like receptor agonist and D2-like receptor antagonist. In behavioral experiments, L-SPD dose-dependently attenuated cue plus MDPV-primed reinstatement of MDPV-seeking behavior in the IVSA model. The highest dose of L-SPD also attenuated MDPV-primed reinstatement of MDPV CPP, as well as cue-induced reinstatement of sucrose-seeking. L-SPD had no significant locomotor effects, and did not modulate the robust hyperactivity induced by MDPV. The current findings show for the first time a robust reinstatement effect with MDPV, which can be reduced by L-SPD. These results establish a role for DA receptors in drug-seeking behavior for MDPV.

Indexed as

AnimalsBehavior, AnimalBenzodioxolesBerberineCocaineDopamine AgonistsDopamine AntagonistsDrug-Seeking BehaviorExtinction, PsychologicalHumansPyrrolidinesRats, Sprague-DawleyReceptors, Dopamine D1Synthetic CathinoneBenzodioxolesBerberineCocaineDopamine AgonistsDopamine AntagonistsPyrrolidinesReceptors, Dopamine D1stepholidineSynthetic Cathinoneconditioned place preferencedopamine receptorMDPVreinstatementself-administrationStepholidine

Identifiers

PMID29597343
PMCPMC6062002
OpenAlexW2795359775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.